Early research suggests first immunotherapy for mesothelioma on the horizon – Medical Xpress
|
Early research suggests first immunotherapy for mesothelioma on the horizon
Medical Xpress Early findings from an ongoing phase II clinical trial in France, MAPS-2, show that immunotherapy may slow the growth of MPM after relapse. At 12 weeks, cancer had not worsened in 44% of patients who received nivolumab (Opdivo) and in 50% of those who … |
